Natco Pharma Ltd
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1]
NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.[2]
- Market Cap ₹ 25,203 Cr.
- Current Price ₹ 1,407
- High / Low ₹ 1,639 / 752
- Stock P/E 15.4
- Book Value ₹ 327
- Dividend Yield 0.68 %
- ROCE 30.1 %
- ROE 25.9 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 24.9%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty Total Market Nifty Smallcap 250 BSE 250 SmallCap Index Nifty MidSmall Healthcare Nifty500 Multicap India Manufacturing 50:30:20
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
661 | 739 | 825 | 1,042 | 2,020 | 2,185 | 2,094 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,221 | |
511 | 560 | 615 | 777 | 1,337 | 1,256 | 1,300 | 1,332 | 1,446 | 1,681 | 1,772 | 2,245 | 2,193 | |
Operating Profit | 150 | 179 | 210 | 266 | 683 | 928 | 795 | 583 | 606 | 264 | 936 | 1,754 | 2,028 |
OPM % | 23% | 24% | 25% | 25% | 34% | 42% | 38% | 30% | 30% | 14% | 35% | 44% | 48% |
1 | 17 | 0 | 12 | 14 | 40 | 130 | 107 | 104 | 99 | 105 | 126 | 156 | |
Interest | 26 | 37 | 32 | 23 | 18 | 15 | 19 | 22 | 13 | 18 | 14 | 19 | 20 |
Depreciation | 22 | 30 | 47 | 51 | 54 | 66 | 81 | 100 | 117 | 143 | 164 | 187 | 187 |
Profit before tax | 102 | 129 | 132 | 204 | 624 | 887 | 825 | 569 | 580 | 202 | 862 | 1,674 | 1,977 |
Tax % | 36% | 24% | 1% | 24% | 22% | 22% | 22% | 19% | 24% | 16% | 17% | 17% | |
66 | 98 | 130 | 156 | 485 | 695 | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,636 | |
EPS in Rs | 4.58 | 6.21 | 8.10 | 9.02 | 27.88 | 37.74 | 35.24 | 25.31 | 24.18 | 9.31 | 39.18 | 77.51 | 91.37 |
Dividend Payout % | 17% | 16% | 12% | 14% | 24% | 22% | 18% | 27% | 22% | 48% | 14% | 12% |
Compounded Sales Growth | |
---|---|
10 Years: | 18% |
5 Years: | 14% |
3 Years: | 25% |
TTM: | 42% |
Compounded Profit Growth | |
---|---|
10 Years: | 30% |
5 Years: | 17% |
3 Years: | 49% |
TTM: | 101% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 19% |
3 Years: | 20% |
1 Year: | 84% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 14% |
3 Years: | 16% |
Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 31 | 33 | 33 | 35 | 35 | 37 | 36 | 36 | 36 | 36 | 36 | 36 |
Reserves | 502 | 693 | 813 | 1,261 | 1,614 | 3,035 | 3,452 | 3,737 | 4,085 | 4,227 | 4,837 | 5,817 |
338 | 240 | 312 | 113 | 222 | 173 | 386 | 316 | 268 | 416 | 167 | 371 | |
209 | 229 | 226 | 413 | 446 | 470 | 428 | 498 | 403 | 430 | 617 | 682 | |
Total Liabilities | 1,080 | 1,196 | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 |
583 | 645 | 710 | 710 | 833 | 1,019 | 1,227 | 1,584 | 2,023 | 2,312 | 2,427 | 2,491 | |
CWIP | 106 | 124 | 129 | 212 | 336 | 480 | 638 | 518 | 223 | 130 | 64 | 137 |
Investments | 2 | 2 | 2 | 22 | 32 | 76 | 169 | 112 | 304 | 308 | 392 | 539 |
389 | 425 | 543 | 878 | 1,116 | 2,140 | 2,270 | 2,373 | 2,242 | 2,360 | 2,774 | 3,739 | |
Total Assets | 1,080 | 1,196 | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
61 | 144 | 93 | 112 | 346 | 464 | 669 | 417 | 299 | 46 | 849 | 1,212 | |
-111 | -108 | -120 | -176 | -299 | -1,116 | -611 | -175 | -107 | 4 | -465 | -1,026 | |
26 | -35 | 29 | 154 | -48 | 651 | -51 | -251 | -186 | 35 | -363 | -247 | |
Net Cash Flow | -24 | 0 | 2 | 90 | -1 | -2 | 7 | -8 | 6 | 85 | 21 | -62 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 72 | 59 | 85 | 92 | 86 | 106 | 88 | 105 | 73 | 116 | 115 | 109 |
Inventory Days | 220 | 283 | 331 | 482 | 213 | 389 | 545 | 534 | 570 | 496 | 432 | 357 |
Days Payable | 159 | 172 | 189 | 372 | 160 | 239 | 224 | 244 | 104 | 105 | 153 | 120 |
Cash Conversion Cycle | 132 | 170 | 228 | 202 | 138 | 257 | 410 | 395 | 539 | 507 | 394 | 345 |
Working Capital Days | 67 | 71 | 99 | 131 | 111 | 244 | 275 | 355 | 294 | 333 | 220 | 184 |
ROCE % | 17% | 18% | 17% | 18% | 39% | 35% | 23% | 14% | 13% | 4% | 18% | 30% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
4 Nov - Appointment of Mr. Imtiyaz Basade as Senior VP.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
30 Oct - Q2FY25 Unaudited Financial Results Earnings Call
-
Board Meeting Intimation for Considering The Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2024 And 2Nd Interim Dividend, If Any
28 Oct - Board meeting to discuss financial results and interim dividend.
-
Announcement under Regulation 30 (LODR)-Change in Management
11 Oct - Mr. Vamsi Krishna Mutyala appointed as Associate VP – CSR.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Oct - Certificate under Regulation 74(5) for Q3 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT REC
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jul 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Sep 2019TranscriptNotesPPT
-
Aug 2019TranscriptPPT
-
Jun 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
May 2017TranscriptPPT
-
Feb 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Sep 2016TranscriptNotesPPT
-
Aug 2016TranscriptPPT
-
Jun 2016TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
Exports of formulations - Complex Generics [1]
The company is focused on niche opportunities in the US.
Focus on Para IV and First-to-File molecules
Started winning tenders in Asian markets including Malaysia and Thailand
Company is focused on high-barrier-to-entry products that are typically characterized by one or more of the following: Intricate Chemistry, Challenging delivery systems, Difficult or complex manufacturing process